shadow_tr
urology
Tulane Urology
home
facultyover
research
residency
fellowship
procedures
clinic
patient information
newsletters
Blue_divider
Urology Health Guide
 
 
 
Prostate Cancer

Have you been diagnosed with prostate cancer? Our informational site myprostatecancer.com is your source for recent news, treatment options, and information.

Visit myprostatecancer.com

 
 
 
 
Kidney Cancer

If you have been diagnosed with kidney cancer, please visit our informational site savethekidney.net for recent news, treatment options, and information on kidney cancer. 

savethekidney.net

 
Research Projects at Tulane Urology
Oliver Sartor, MD

Oliver Sartor, MD


Dr. Sartor has been involved in a leadership role with a Phase III trial prolonging survival in advanced prostate cancer.  Given that there are only five trials in history to obtain this feat, the fact that Dr. Sartor has been involved in two out of the five in a leadership role has been notable. 

The first trial involved second-line chemotherapy with Cabazitaxel and this trial has now been published in Lancet as well as gaining FDA approval in June 2010.  It is the first trial to demonstrate a survival benefit after initial chemotherapy had failed.  Dr. Sartor was the international co-principal investigator for this trial, and senior author on the Lancet paper.

In the new trial, recently announced, the use of the new isotope Radium 223 has resulted in a prolong survival of a polaroid of patients with advanced metastatic prostate cancer and this is the first radio-pharmaceutical to prolong life in prostate cancer and in all likelihood will result in a FDA approval.  Dr. Sartor was the North American principal-investigator in this trial.

Dr. Sartor was a local investigator (but without a national leadership role) in a third trial which led to a prolongation in survival in metastatic prostate cancer using Abiraterone.  He currently is involved with his fourth Abiraterone study here at Tulane which is the first second-line hormonal agent to demonstrate survival benefits.  Abiraterone is now FDA approved.

He currently runs approximately ten clinical trials in prostate cancer and is a national co-principal investigator in three of these trials.

 

Dr MageedAsim Abdel-Mageed, PhD

Active Research Projects

"Targeting Tumor-Derived exRNA-Containing Microvesicles by High Throughput Screening"

"Estrogen-ER Axis in Disparity of Prostate Cancer"

"Adipose stem cell-based therapeutic targeting of residual androgens in African Americans with bone metastatic prostate cancer" Co-Invest: Raju Thomas, K. Moparty

Dr. Abdel-Mageed's laboratory primarily focuses on basic research into the cellular and molecular aspects of urologic diseases, with particular attention given to prostate and bladder cancer. The laboratory has a special interest in identifying molecular determinants of prostate cancer progression using in vitro and in vivo experimental approaches.



Suresh Sikka, PhDSuresh Sikka, PhD

Men's Health (Male Infertility, Sexual Dysfunction, Genitourinary Inflammation, Prostate Diseases, Environmental Reproductive Toxicology, Role of Oxidative Stress/Antioxidants, Sperm Safety Multicenter Clinical Studies, Forensic APplications, Endocrine Disruptors, and Andropause)

Male Infertility

  • Diagnosis
  • Treatment
  • Assisted Reproduction TEchnology (ART)
  • Oxidative Stress and Role of Antioxidants
  • Testicular Toxicology
  • Standardized S/E Training Program
  • DNA Identification
  • Chromosome Evaluation
Sexual Health
  • Erectile Dysfunction (ED)
  • Peyronie's Disease
  • Oxidative Stress and Role of Antioxidants
  • Role of Stem Cells

Prostate Health

  • BPH
  • Prostatitis and GUI
  • Lower Urinary Tract Symptoms (LUTS)
  • Male Aging (Andropause)
  • Hypogonadism & Hormone REplacement
  • Prostate Cancer


 

Department of Urology, 1430 Tulane Avenue, SL-42, New Orleans, LA 70112 504-988-2750 urology@tulane.edu